2. Academic Validation
  3. A rational utilization of high-throughput screening affords selective, orally bioavailable 1-benzyl-3-carboxyazetidine sphingosine-1-phosphate-1 receptor agonists

A rational utilization of high-throughput screening affords selective, orally bioavailable 1-benzyl-3-carboxyazetidine sphingosine-1-phosphate-1 receptor agonists

  • J Med Chem. 2004 Dec 30;47(27):6662-5. doi: 10.1021/jm0492507.
Jeffrey J Hale 1,  Christopher L Lynch,  William Neway,  Sander G Mills,  Richard Hajdu,  Carol Ann Keohane,  Mark J Rosenbach,  James A Milligan,  Gan-Ju Shei,  Stephen A Parent,  Gary Chrebet,  James Bergstrom,  Deborah Card,  Marc Ferrer,  Peter Hodder,  Berta Strulovici,  Hugh Rosen,  Suzanne Mandala
Affiliations

Affiliation

  • 1 Department of Medicinal Chemistry, Merck Research Laboratories, Rahway, New Jersey 07065, USA. jeffrey_hale@merck.com
PMID: 15615513 DOI: 10.1021/jm0492507
Abstract

Moderately potent, selective S1P(1) receptor agonists identified from high-throughput screening have been adapted into lipophilic tails for a class of orally bioavailable amino acid-based S1P(1) agonists represented by 7. Many of the new compounds are potent S1P(1) agonists that select against the S1P(2), S1P(3), and S1P(4) (although not S1P(5)) receptor subtypes. Analogues 18 and 24 are highly orally bioavailable and possess excellent pharmacokinetic profiles in the rat, dog, and rhesus monkey.

Figures